Immunethep awarded funding from PACE to advance monoclonal antibodies programme

Immunethep has been awarded £1M in funding from PACE to advance monoclonal antibodies that restore the ability to control bacterial infection.

• Funding the development of monoclonal antibodies targeting infections caused by Escherichia coli and Klebsiella pneumoniae.

• This immunotherapy allows the immune system to restore its ability to control bacterial infections without inducing antimicrobial resistance.

Download the Press Release below:

IMTP_Press-release_PACE_EN_20250402.pdf